2022 Volume 81 Issue 4 Pages 187-192
Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has been shown to be effective in the treatmentof patients with metastatic castration-resistant prostate cancer (mCRAP) who have BRCA1/2 or ATM mutations,which are DNA repair genes. In addition to ovarian, breast, and pancreatic cancer, the indication was extended to“castration-resistant prostate cancer with BRCA mutation-positive distant metastasis” in December 2020 in Japan.Prostate cancer has also entered the era of “personalized cancer treatment based on genetic information,” or socalled “cancer genome medicine.”This article will discuss the following: 1) the relationship between DNA repair genes and prostate cancercarcinogenesis, 2) the mechanism of PARP inhibitors, 3) the results of the PROfound clinical trial of olaparib, and4) the timing of genetic testing for prostate cancer.
